GILD Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

146.920

Open

143.500

VWAP

145.68

Vol

5.21M

Mkt Cap

182.03B

Low

143.485

Amount

759.06M

EV/EBITDA(TTM)

13.71

Total Shares

1.24B

EV

199.25B

EV/OCF(TTM)

19.89

P/S(TTM)

6.25

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.

Show More

Events Timeline

(ET)

2026-02-25

13:50:00

Gilead Sciences Presents New ARTISTRY-1 and ARTISTRY-2 Trial Data

2026-02-23 (ET)

2026-02-23

18:20:00

Stifel Downgrades Arcellx to Hold, Price Target Cut to $115

2026-02-23

16:30:00

Major Averages Drop Over 1% Due to Tariff Policy

2026-02-23

12:00:00

Major Averages Drop Over 1% Due to Tariff Policy

2026-02-23

06:10:00

Gilead to Acquire Arcellx for $115 per Share

2026-02-23

06:10:00

Gilead Acquires Arcellx for $115 per Share

News

NASDAQ.COM

03-09NASDAQ.COM

PinnedGilead Sciences Stock Rises Ahead of Positive Earnings Outlook

Marketbeat

03-08Marketbeat

Three Blue-Chip Stocks Designed for a Shifting Market

CNBC

FDA Vaccine and Biotech Chief Resigns Amid Industry Criticism

NASDAQ.COM

03-06NASDAQ.COM

Analysis of QQQM ETF's 52-Week Price Fluctuations

seekingalpha

03-06seekingalpha

Stock Futures Plunge as Jefferies Faces Lawsuit Over $126.4M Claim

Marketbeat

03-06Marketbeat

Three Cash Flow Generators Offer Stability in Volatile Markets

19 Analyst Rating

Wall Street analysts forecast GILD stock price to rise

16 Buy

3 Hold

0 Sell

Strong Buy

Current: 0.000

Low

105.00

Averages

137.88

High

154.00

Current: 0.000

Low

105.00

Averages

137.88

High

154.00

Mizuho

Outperform

maintain

$140 -> $170

AI Analysis

2026-02-19

Reason

Mizuho

Price Target

$140 -> $170

AI Analysis

2026-02-19

maintain

Outperform

Reason

Mizuho raised the firm's price target on Gilead to $170 from $140 and keeps an Outperform rating on the shares.

Barclays

Equal Weight

initiated

$155

2026-02-19

Reason

Barclays

Price Target

$155

2026-02-19

initiated

Equal Weight

Reason

Barclays initiated coverage of Gilead with an Equal Weight rating and $155 price target. The company is back to doing what it does best, which is developing treatments for infectious diseases, the analyst tells investors in a research note. However, Barclays views Gilead's valuation as "rich" at current share levels.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GILD

Unlock Now

Valuation Metrics

The current forward P/E ratio for Gilead Sciences Inc (GILD.O) is 14.44, compared to its 5-year average forward P/E of 11.76. For a more detailed relative valuation and DCF analysis to assess Gilead Sciences Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

11.76

Current PE

14.44

Overvalued PE

14.31

Undervalued PE

9.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

8.70

Current EV/EBITDA

9.78

Overvalued EV/EBITDA

9.90

Undervalued EV/EBITDA

7.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

3.74

Current PS

5.04

Overvalued PS

4.34

Undervalued PS

3.14

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what are the best stocks right now

Intellectia · 72 candidates

Region: USAnalyst Consensus: Strong Buy, Moderate BuyEps 5yr Cagr: >= 10Pe Ttm: 10 - 35Return On Equity: >= 15.0%Is Index Component: GSPC, NDX

Ticker

Name

Market Cap$

Charles Schwab Corp

166.86B

Gilead Sciences Inc

178.68B

NXP Semiconductors NV

50.98B

Williams Companies Inc

90.69B

Sysco Corp

40.82B

IQVIA Holdings Inc

29.29B

Intellectia · 11 candidates

Market Cap: >= 50.00BAnalyst Consensus: Strong BuyPe Ttm: 12 - 28Return On Equity: >= 15.0%Is Index Component: GSPC

Ticker

Name

Market Cap$

Coca-Cola Co

341.22B

Gilead Sciences Inc

183.52B

Charles Schwab Corp

166.88B

Newmont Corporation

128.93B

Northrop Grumman Corp

107.73B

Western Digital Corp

84.97B

principales acciones que paguen dividendos

Intellectia · 96 candidates

Dividend Yield Ttm: 2 - 8Dividend Payout Ratio: 20.00 - 80.00Is Index Component: GSPCDividend 5yr Cagr: >= 0

Ticker

Name

Market Cap$

Exxon Mobil Corp

642.60B

Johnson & Johnson

599.00B

Home Depot Inc

369.15B

Coca-Cola Co

345.00B

Cisco Systems Inc

313.70B

Merck & Co Inc

300.17B

Featured Screeners

Intellectia · 45 candidates

Market Cap: >= 20.00BEps 5yr Cagr: >= 15Pe Ttm: 15 - 30Moving Average Relationship: PriceAboveMA200Monthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

Taiwan Semiconductor Manufacturing Co Ltd

1.94T

JPMorgan Chase & Co

809.92B

Johnson & Johnson

598.69B

Micron Technology Inc

464.13B

Novartis

321.75B

HSBC Holdings PLC

320.01B

activos con tendencia alcista

Intellectia · 61 candidates

Rsi Category: moderateMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Month Price Change Pct: >= $10.00Is Index Component: GSPC

Ticker

Name

Market Cap$

DaVita Inc

9.87B

Borgwarner Inc

12.78B

GE Vernova Inc

220.35B

Southwest Airlines Co

26.92B

Charter Communications Inc

30.28B

AT&T Inc

195.18B

what best stock to buy right now??

Intellectia · 92 candidates

Market Cap: >= 20.00BNet Margin: >= 10.00Eps 5yr Cagr: >= 10Pe Ttm: 10 - 35List Exchange: XNYS, XNASIs Index Component: GSPC, NDX

Ticker

Name

Market Cap$

Charles Schwab Corp

169.48B

Booking Holdings Inc

137.64B

Gilead Sciences Inc

189.55B

NXP Semiconductors NV

59.73B

Kinder Morgan Inc

71.84B

Wells Fargo & Co

273.88B

Intellectia · 86 candidates

Net Margin: >= 10.00Pe Ttm: 10 - 30Return On Equity: >= 10.0%Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

Berkshire Hathaway Inc

1.08T

JPMorgan Chase & Co

832.79B

Johnson & Johnson

590.40B

Micron Technology Inc

473.78B

Bank of America Corp

384.86B

Procter & Gamble Co

366.54B

what stocks would you buy right now

Intellectia · 38 candidates

Eps 5yr Cagr: >= 8Pe Ttm: 10 - 30Return On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

Gilead Sciences Inc

192.33B

NXP Semiconductors NV

61.52B

Sysco Corp

43.37B

United Parcel Service Inc

101.16B

American Express Co

231.73B

Deckers Outdoor Corp

16.43B

give me top 5 screener

Intellectia · 62 candidates

Region: USMarket Cap Category: large, megaNet Margin: >= 10.00Eps 5yr Cagr: >= 10Pe Ttm: 10 - 35Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC

Ticker

Name

Market Cap$

Alphabet Inc

3.70T

JPMorgan Chase & Co

823.62B

Johnson & Johnson

586.69B

Micron Technology Inc

463.33B

Bank of America Corp

379.02B

Caterpillar Inc

362.31B

which stock you will pick for today to buy?

Intellectia · 585 candidates

Moving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 55One Day Predict Return: >= 0.0%

Ticker

Name

Market Cap$

Gilead Sciences Inc

193.35B

Hooker Furnishings Corp

164.25M

BOK Financial Corp

8.22B

Kornit Digital Ltd

789.81M

Mercantile Bank Corp

923.14M

Fifth Third Bancorp

59.06B

Whales Holding GILD

Pacific Investment Management Company LLC

Mubadala Investment Company PJSC

Pacer Advisors, Inc.

Fubon Asset Management Co., Ltd.

Boston Partners Global Investors, Inc.

Middlefield Capital Corporation

Trading Trends

People Also Watch

Frequently Asked Questions

What is Gilead Sciences Inc (GILD) stock price today?

The current price of GILD is 146.63 USD — it has increased 1.88

What is Gilead Sciences Inc (GILD)'s business?

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.

What is the price predicton of GILD Stock?

Wall Street analysts forecast GILD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GILD is137.88 USD with a low forecast of 105.00 USD and a high forecast of 154.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Gilead Sciences Inc (GILD)'s revenue for the last quarter?

Gilead Sciences Inc revenue for the last quarter amounts to 7.92B USD, increased 4.70

What is Gilead Sciences Inc (GILD)'s earnings per share (EPS) for the last quarter?

Gilead Sciences Inc. EPS for the last quarter amounts to 1.74 USD, increased 25.18

How many employees does Gilead Sciences Inc (GILD). have?

Gilead Sciences Inc (GILD) has 17000 emplpoyees as of March 10 2026.

What is Gilead Sciences Inc (GILD) market cap?

Today GILD has the market capitalization of 182.03B USD.